Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells

Molecular Pharmaceutics

Volumn 3, Issue 5, 2006, Pages 579-588

  Li, Shyh Dar ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antisense oligodeoxynucleotide; Lung cancer; siRNA; Survivin; Targeted delivery

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANISAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CATION; CHOLESTEROL; LIGAND; LIPOSOME; NANOPARTICLE; POLYCATION; PROTAMINE; SIGMA OPIATE RECEPTOR; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CATTLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG CANCER; PRIORITY JOURNAL; THYMUS; TUMOR CELL; TUMOR GROWTH;

CELL LINE, TUMOR; CELL SURVIVAL; DNA; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR STRUCTURE; NANOPARTICLES; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 33750417183     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060039w     Document Type: Article

References (44)

1. Patel, J. D.; Bach, P. B.; Kris, M. G. Lung cancer in US women: a contemporary epidemic. J. Am. Med. Assoc. 2004, 291 (14), 1763-8.
2. Olie, R. A.; Simoes-Wust, A. P.; Baumann, B.; Leech, S. H.; Fabbro, D.; Stahel, R. A.; Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60 (11), 2805-9.
3. Cancer Facts and Figures 2004; Atlanta, GA; American Cancer Society, Inc.: 2004; 303294251; pp 1-60; www.cancer.org.
4. Machtay, M.; Jeremic, B. Complex and controversial issues in locally advanced non-small cell lung carcinoma. Semin. Surg. Oncol. 2003, 21 (2), 128-37.
5. Rodriguez, J. A.; Span, S. W.; Ferreira, C. G.; Kruyt, F. A.; Giaccone, G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp. Cell Res. 2002, 275 (1), 44-53.
6. Ambrosini, G.; Adida, C.; Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3 (8), 917-21.
7. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58 (23), 5315-20.
8. Kappler, M.; Kohler, T.; Kampf, C.; Diestelkotter, P.; Wurl, P.; Schmitz, M.; Bartel, F.; Lautenschlager, C.; Rieber, E. P.; Schmidt, H.; Bache, M.; Taubert, H.; Meye, A. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer 2001, 95 (6), 360-3.
9. Kato, J.; Kuwabara, Y.; Mitani, M.; Shinoda, N.; Sato, A.; Toyama, T.; Mitsui, A.; Nishiwaki, T.; Moriyama, S.; Kudo, J.; Fujii, Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 2001, 95 (2), 92-5.
10. Asanuma, K.; Moriai, R.; Yajima, T.; Yagihashi, A.; Yamada, M.; Kobayashi, D.; Watanabe, N. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res. 2000, 91 (11), 1204-9.
11. Li, F. Survivin study: what is the next wave? J. Cell Physiol. 2003, 197 (1), 8-29.
12. Altieri, D. C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22 (53), 8581-9.
13. Tu, S. P.; Jiang, X. H.; Lin, M. C.; Cui, J. T.; Yang, Y.; Lum, C. T.; Zou, B.; Zhu, Y. B.; Jiang, S. H.; Wong, W. M.; Chan, A. O.; Yuen, M. F.; Lam, S. K.; Kung, H. F.; Wong, B. C. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003, 63 (22), 7724-32.
14. Jana, S.; Chakraborty, C.; Nandi, S.; Deb, J. K. RNA interference: potential therapeutic targets. Appl. Microbiol. Biotechnol. 2004, 65 (6), 649-57.
15. Brummelkamp, T. R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2 (3), 243-7.
16. Lewis, D. L.; Wolff, J. A. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol. 2005, 392, 336-50.
17. Weil, D.; Garcon, L.; Harper, M.; Dumenil, D.; Dautry, F.; Kress, M. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques 2002, 33 (6), 1244-8.
18. Xiuzhu, T.; Shore, L.; Stram, Y.; Michaeli, S. C.; Brietbart, H. C.; Shemesh, M. Duplexes of 21 nucleotide RNA specific for COX II mediates RNA interference in cultured bovine aortic coronary endothelial cells (BAECs). Prostaglandins Other Lipid Mediators 2003, 71 (3-4), 119-29.
19. Li, S.; Rizzo, M. A.; Bhattacharya, S.; Huang, L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 1998, 5 (7), 930-7.
20. Li, S.; Huang, L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 1997, 4 (9), 891-900.
21. Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer 2004, 112 (4), 693-700.
22. Li, F.; Ling, X.; Huang, H.; Brattain, L.; Apontes, P.; Wu, J.; Binderup, L.; Brattain, M. G. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 2005, 24 (8), 1385-95.
23. Chao, J. I.; Kuo, P. C.; Hsu, T. S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J. Biol. Chem. 2004, 279 (19), 20267-76.
24. Chao, J. I.; Liu, H. F. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol. Pharmacol. 2006, 69 (1), 154-64.
25. John, C. S.; Bowen, W. D.; Varma, V. M.; McAfee, J. G.; Moody, T. W. Sigma receptors are expressed in human nonsmall cell lung carcinoma. Life Sci. 1995, 56 (26), 2385-92.
26. Kuo, P. C.; Liu, H. F.; Chao, J. I. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J. Biol. Chem. 2004, 279 (53), 55875-85.
27. Cui, Z.; Han, S. J.; Vangasseri, D. P.; Huang, L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm. 2005, 2 (1), 22-8.
28. Ishida, T.; Iden, D. L.; Allen, T. M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999, 460 (1), 129-33.
29. Perouzel, E.; Jorgensen, M. R.; Keller, M.; Miller, A. D. Synthesis and formulation of neoglycolipids for the functionalization of liposomes and lipoplexes. Bioconjugate Chem. 2003, 14 (5), 884-98.
30. Peng, X. H.; Cao, Z. H.; Xia, J. T.; Carlson, G. W.; Lewis, M. M.; Wood, W. C.; Yang, L. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res. 2005, 65 (5), 1909-17.
31. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Delivery Rev. 2004, 56 (11), 1649-59.
32. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Woodle, M. C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32 (19), e149.
33. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42 (4), 355-402.
34. John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res. 1999, 59 (18), 4578-83.
35. John, C. S.; Bowen, W. D.; Fisher, S. J.; Lim, B. B.; Geyer, B. C.; Vilner, B. J.; Wahl, R. L. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1′-piperidinyl)ethyl]-3-[125I]iodo-4- methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl. Med. Biol. 1999, 26 (4), 377-82.
36. John, C. S.; Bowen, W. D.; Saga, T.; Kinuya, S.; Vilner, B. J.; Baumgold, J.; Paik, C. H.; Reba, R. C.; Neumann, R. D.; Varma, V. M.; et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J. Nucl. Med. 1993, 34 (12), 2169-75.
37. John, C. S.; Gulden, M. E.; Vilner, B. J.; Bowen, W. D. Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N-[2-(4-iodophenyl)ethyl] -N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. Nucl. Med. Biol. 1996, 23 (6), 761-6.
38. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new σ receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J. Med. Chem. 1994, 37 (12), 1737-9.
39. John, C. S.; Vilner, B. J.; Gulden, M. E.; Efange, S. M.; Langason, R. B.; Moody, T. W.; Bowen, W. D. Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res. 1995, 55 (14), 3022-7.
40. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55 (2), 408-13.
41. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268 (1), 9-18.
42. Wolfe, S. A., Jr.; Culp, S. G.; De Souza, E. B. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989, 124 (3), 1160-72.
43. Yoshioka, H. Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. Biomaterials 1991, 12 (9), 861-4.
44. van Engeland, M.; Ramaekers, F. C.; Schutte, B.; Reutelingsperger, C. P. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996, 24 (2), 131-9.